Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1984 Mar;19(3):412-6.
doi: 10.1128/jcm.19.3.412-416.1984.

In vitro susceptibilities of sucrose-negative Candida tropicalis, Candida lusitaniae, and Candida norvegensis to amphotericin B, 5-fluorocytosine, miconazole, and ketoconazole

In vitro susceptibilities of sucrose-negative Candida tropicalis, Candida lusitaniae, and Candida norvegensis to amphotericin B, 5-fluorocytosine, miconazole, and ketoconazole

D G Ahearn et al. J Clin Microbiol. 1984 Mar.

Abstract

The MICs and minimal lethal concentrations of four antimycotics, amphotericin B, 5-fluorocytosine, miconazole nitrate, and ketoconazole, were determined for 25 yeast isolates representing species uncommonly implicated in candidiasis. A microdilution procedure was employed with complex and synthetic media. The isolates, in general, were susceptible to the same antimicrobial agents shown to be effective against Candida albicans, but differences between some of the species in relative susceptibilities to the antifungal agents were noted. Isolates of atypical sucrose-negative Candida tropicalis were similar in their susceptibility patterns to typical isolates of the species. Relative resistance to amphotericin B, miconazole nitrate, and ketoconazole was noted for two Candida lusitaniae isolates, but all strains were susceptible to 5-fluorocytosine. Candida norvegensis isolates were more resistant to miconazole and ketoconazole than C. albicans clinical isolates. The microtiter system was satisfactory for determining minimal inhibitory concentrations, but the system is not recommended for detecting finite differences in drug susceptibilities or for detecting drug synergism.

PubMed Disclaimer

References

    1. Sabouraudia. 1975 Mar;13 Pt 1:63-73 - PubMed
    1. J Infect Dis. 1976 Oct;134(4):336-41 - PubMed
    1. J Clin Microbiol. 1977 Apr;5(4):494-6 - PubMed
    1. Antonie Van Leeuwenhoek. 1978;44(1):15-24 - PubMed
    1. Am J Clin Pathol. 1979 Aug;72(2):194-8 - PubMed

LinkOut - more resources